Protocols›Performance & endurance›Strongman / Powerlifting
← Protocols
Athlete / performance · uptakeCommunity · convergenceNo approved clinical use

Strongman / Powerlifting

Stack: BPC-157 + TB-500 + MGF + IGF-1 LR3 · strength recovery / output
"A maximal-strength recovery/output stack that adds IGF-1 LR3 — the point where 'community reference' meets real risk. Weak human evidence, presented as information only."
GoalStrength recovery / output
Compounds4 · BPC-157 + TB-500 + MGF + IGF-1 LR3
Humans exposed (est.)Moderate — undocumented
StatusMHRA (UK): not licensed medicines here · FDA (US): not approved · IGF-1 LR3 carries real risk
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Athlete / performance
Where / who
Community / athlete and clinic use as tagged above.
Use status
Used in strength circles.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
BPC-157 / TB-500: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing; removed from Category 2 Apr 2026, 503A Bulks List decision pending the PCAC meeting 23–24 Jul 2026.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Weak/absent human evidence; IGF-1 LR3 risk.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Why this combination

The repair pair plus MGF and IGF-1 LR3 for direct anabolic intent. IGF-1 LR3 carries a real risk profile and has no human efficacy trials for this use. This is documented as community reference, not endorsement.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription. Specific timing is part of membership.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Moderate

Used in strength circles.

Human efficacy None

Weak/absent human evidence; IGF-1 LR3 risk.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Higher risk, not higher evidence.

Fast facts
Compounds

BPC-157 · TB-500 · MGF · IGF-1 LR3

Humans exposed (est.)

Moderate — undocumented.

UK strip

GREEN — research material